CN116370571A - 一种中药组合物、复方汤药及其制备方法及应用 - Google Patents
一种中药组合物、复方汤药及其制备方法及应用 Download PDFInfo
- Publication number
- CN116370571A CN116370571A CN202310121339.6A CN202310121339A CN116370571A CN 116370571 A CN116370571 A CN 116370571A CN 202310121339 A CN202310121339 A CN 202310121339A CN 116370571 A CN116370571 A CN 116370571A
- Authority
- CN
- China
- Prior art keywords
- decoction
- depression
- chinese medicine
- parts
- traditional chinese
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 89
- 239000000203 mixture Substances 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 150000001875 compounds Chemical class 0.000 title abstract description 6
- 206010070606 Post stroke depression Diseases 0.000 claims abstract description 28
- 240000000249 Morus alba Species 0.000 claims abstract description 9
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 9
- 240000001398 Typha domingensis Species 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 238000002791 soaking Methods 0.000 claims description 2
- 210000002216 heart Anatomy 0.000 abstract description 19
- 210000000952 spleen Anatomy 0.000 abstract description 14
- 240000002948 Ophiopogon intermedius Species 0.000 abstract description 6
- 241001061264 Astragalus Species 0.000 abstract description 5
- 235000006533 astragalus Nutrition 0.000 abstract description 5
- 210000004233 talus Anatomy 0.000 abstract description 5
- 230000008506 pathogenesis Effects 0.000 abstract description 3
- 241000756943 Codonopsis Species 0.000 abstract description 2
- 229940088592 immunologic factor Drugs 0.000 abstract description 2
- 241001080798 Polygala tenuifolia Species 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 description 26
- 210000004369 blood Anatomy 0.000 description 24
- 239000008280 blood Substances 0.000 description 24
- 238000003745 diagnosis Methods 0.000 description 22
- 208000024891 symptom Diseases 0.000 description 21
- 206010033557 Palpitations Diseases 0.000 description 20
- 208000011580 syndromic disease Diseases 0.000 description 19
- 210000002784 stomach Anatomy 0.000 description 18
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 17
- 206010022437 insomnia Diseases 0.000 description 16
- 230000001976 improved effect Effects 0.000 description 15
- 239000011248 coating agent Substances 0.000 description 14
- 238000000576 coating method Methods 0.000 description 14
- 208000019901 Anxiety disease Diseases 0.000 description 13
- 230000036506 anxiety Effects 0.000 description 13
- 210000003205 muscle Anatomy 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 230000008451 emotion Effects 0.000 description 12
- 210000003414 extremity Anatomy 0.000 description 12
- 210000004072 lung Anatomy 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 230000006870 function Effects 0.000 description 10
- 210000004185 liver Anatomy 0.000 description 10
- 206010008190 Cerebrovascular accident Diseases 0.000 description 9
- 230000002490 cerebral effect Effects 0.000 description 9
- 230000004069 differentiation Effects 0.000 description 9
- 210000001364 upper extremity Anatomy 0.000 description 9
- 206010022998 Irritability Diseases 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- 210000001367 artery Anatomy 0.000 description 8
- 210000003734 kidney Anatomy 0.000 description 8
- 206010062717 Increased upper airway secretion Diseases 0.000 description 7
- 206010024642 Listless Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 208000002173 dizziness Diseases 0.000 description 7
- 230000001939 inductive effect Effects 0.000 description 7
- 208000017971 listlessness Diseases 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 208000026435 phlegm Diseases 0.000 description 7
- 210000003625 skull Anatomy 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 241000233948 Typha Species 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 230000007958 sleep Effects 0.000 description 6
- 210000001685 thyroid gland Anatomy 0.000 description 6
- 241000208966 Polygala Species 0.000 description 5
- 230000004596 appetite loss Effects 0.000 description 5
- 210000000988 bone and bone Anatomy 0.000 description 5
- 206010008118 cerebral infarction Diseases 0.000 description 5
- 208000026106 cerebrovascular disease Diseases 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 206010061428 decreased appetite Diseases 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 238000002636 symptomatic treatment Methods 0.000 description 5
- 230000004580 weight loss Effects 0.000 description 5
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 208000031481 Pathologic Constriction Diseases 0.000 description 4
- 208000022531 anorexia Diseases 0.000 description 4
- 230000002146 bilateral effect Effects 0.000 description 4
- 208000034158 bleeding Diseases 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 206010013781 dry mouth Diseases 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 230000007849 functional defect Effects 0.000 description 4
- 208000020016 psychiatric disease Diseases 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 230000036262 stenosis Effects 0.000 description 4
- 208000037804 stenosis Diseases 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 3
- 206010008479 Chest Pain Diseases 0.000 description 3
- 208000020401 Depressive disease Diseases 0.000 description 3
- 208000001431 Psychomotor Agitation Diseases 0.000 description 3
- 206010038743 Restlessness Diseases 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000002583 angiography Methods 0.000 description 3
- 230000036528 appetite Effects 0.000 description 3
- 235000019789 appetite Nutrition 0.000 description 3
- 210000001627 cerebral artery Anatomy 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000003657 middle cerebral artery Anatomy 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 2
- 208000000044 Amnesia Diseases 0.000 description 2
- 208000031091 Amnestic disease Diseases 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 206010013954 Dysphoria Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 206010019468 Hemiplegia Diseases 0.000 description 2
- 206010062519 Poor quality sleep Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000006986 amnesia Effects 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940107666 astragalus root Drugs 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000001168 carotid artery common Anatomy 0.000 description 2
- 210000000269 carotid artery external Anatomy 0.000 description 2
- 210000004004 carotid artery internal Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229960002464 fluoxetine Drugs 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- 208000034783 hypoesthesia Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 230000010410 reperfusion Effects 0.000 description 2
- 229960002073 sertraline Drugs 0.000 description 2
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical group C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 230000002936 tranquilizing effect Effects 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- 229960004688 venlafaxine Drugs 0.000 description 2
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 2
- GLQPTZAAUROJMO-UHFFFAOYSA-N 4-(3,4-dimethoxyphenyl)benzaldehyde Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC=C(C=O)C=C1 GLQPTZAAUROJMO-UHFFFAOYSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- 206010008089 Cerebral artery occlusion Diseases 0.000 description 1
- 241000007126 Codonopsis pilosula Species 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 206010011469 Crying Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- 206010013789 Dry throat Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 206010021703 Indifference Diseases 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 240000005001 Paeonia suffruticosa Species 0.000 description 1
- 235000003889 Paeonia suffruticosa Nutrition 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 229940121991 Serotonin and norepinephrine reuptake inhibitor Drugs 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 206010041956 Stasis syndrome Diseases 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229960002629 agomelatine Drugs 0.000 description 1
- YJYPHIXNFHFHND-UHFFFAOYSA-N agomelatine Chemical compound C1=CC=C(CCNC(C)=O)C2=CC(OC)=CC=C21 YJYPHIXNFHFHND-UHFFFAOYSA-N 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 208000005634 blind loop syndrome Diseases 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000001037 epileptic effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000007160 gastrointestinal dysfunction Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 231100000861 limb weakness Toxicity 0.000 description 1
- 208000027905 limb weakness Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 201000007309 middle cerebral artery infarction Diseases 0.000 description 1
- 230000007971 neurological deficit Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000001561 neurotransmitter reuptake Effects 0.000 description 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 1
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229960005017 olanzapine Drugs 0.000 description 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940053544 other antidepressants in atc Drugs 0.000 description 1
- 229940054010 other antipsychotics in atc Drugs 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 229960003660 sertraline hydrochloride Drugs 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000027765 speech disease Diseases 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/69—Polygalaceae (Milkwort family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及中药配方领域,特别是涉及一种治疗抑郁症的组合物、复方汤药及其制备方法及应用。一种治疗抑郁症的组合物,按重量份计,包括以下组分,麦冬15~40份;黄芪10~40份;龙骨5~30份;石菖蒲10~30份;蒲黄5~25;远志10~30份;桑叶5~20份;党参10~35份;丹皮5~20份。本发明中的复方汤药包括治疗抑郁症的组合物。本发明还提供了治疗抑郁症复方汤药的制备方法及应用。本发明适用于卒中后抑郁患者,针对郁损心脾内热之病机,调整免疫因子水平,显著改善卒中后抑郁患者日常生活能力。
Description
技术领域
本发明涉及中药配方领域,特别是涉及一种中药组合物、复方汤药及其制备方法及应用。
背景技术
中风是世界第三致死和致残原因的疾病。我国脑卒中发病率整体呈上升趋势,目前,40-75岁居民首次脑卒中标化发病率每年增长8.3%,我国40岁及以上人群脑卒中现患人数达1318万,中风后1年内超过1/3的患者合并有抑郁,而中国卒中后抑郁(Post-strokeDepression,PSD)的发生率和预后前瞻性队列研究(PRIOD研究)发现,与脑卒中后不伴有抑郁患者相比,卒中后抑郁患者的1年脑卒中复发风险增加49%。
卒中后抑郁作为中风后最常见的并发症之一,以其高致病率,复发率成为全球公共健康问题,广泛受到世人关注。卒中后抑郁会导致中风后病人住院时间延长,康复治疗效果不佳,生活质量下降,死亡率增加,给家庭及社会带来极大的负担,因而卒中后抑郁愈来愈得到目前研究的重视。
卒中后抑郁属中医学郁证与中风之合病,就其因果关系而言,郁证为中风之变证,系“因病而郁”。中医虽无卒中后抑郁之病名,但其忧思多虑核心症状跟抑郁相同,属中医“郁病”范畴,为七情之一。中风日久,脑损神戚,认知发生改变,加之长期卧床,生活不能自理,易致亲属冷漠,事业、社会地位丧失,家庭收入下降,对给亲人带来的不便产生强烈的无用感等,促使产生抑郁。
现有的抗抑郁的药物,均以抑制神经递质再摄取,间接提高神经元突触间隙的浓度为治疗靶点。如临床常用的选择性5-羟色胺再吸收抑制剂(SSRI)氟西汀(Fluoxetine),5-羟色胺去甲肾上腺素再摄取抑制剂(SNRIs)文拉法辛(Venlafaxine)等,虽可改善患者的抑郁症状,但因其忽视了中风后抑郁多因素、多靶点的特点,临床应用后,除常见的体重增加、胃肠道功能障碍、性功能障碍、心脏毒性等副作用,还会导致出血风险增加,加剧中风复发,疗效不理想且毒副作用大,因此,开发脑卒中后抑郁的有效的治疗药物迫在眉睫。
发明内容
鉴于以上所述现有技术的缺点,本发明在继承张氏内科学术经验的基础上,通过临证观察,认为卒中后抑郁病机为郁损心脾内热。诚如杨上善《黄帝内经太素》所言:“脾主忧愁……脾为四脏之本,意主愁忧。故心在变动为忧,即意之忧也;或肺在志为忧,亦意之忧也,若在肾志为忧,亦意之忧也。故曰悉忧所在皆脾也。”
本发明的第一方面提供一种中药组合物,其药效成分按重量份计,包括以下组分
优选地,其药效成分按重量份计,包括以下组分,
麦冬:甘、微苦、微寒,质地滋润,入心、肺、胃经。养阴润肺,益胃生津,清心除烦,既能养肺胃之阴而生津润燥,又能清心而除烦热;对此三经,无论是阴虛有热,或温病热邪伤及其阴所致之证,皆为常用要药。尤以养脾胃之阴、生津液之功殊长。故以麦冬为君药,滋脾胃之阴以除热,且功擅清心除烦。
党参:甘,平,归脾、肺经。补脾益肺,养血生津,为补中益气之良药。
黄芪:甘微温,归脾肺经。补气升阳,生津养血,其直接作用在于补气,气旺能生血、摄血行血、行津,故又常用于气血两亏之证,能补气以生血;用于气虚血滞之肢体麻木、半身不遂或痹痛,能补气以行滞。
龙骨:甘、涩,平,归心、肝、肾经。镇惊安神,平肝潜阳,收敛固涩。质重,能镇惊安神,为重镇安神的常用药,宜于心神不宁,心悸失眠,健忘多梦等证。
远志:苦、辛,温,归心、肾、肺经。安神益智,交通心肾,祛痰开窍,辛开苦泄,微温通散,入心、肺、肾经,开心郁,通肾气,使肾气上交于心而安神益智;又祛痰而利心开窍宁神,《药品化义》言:“以此豁痰利窍,使心气开通,则神魄自宁也”,可治多种原因所致的心神不安。
石菖蒲:辛、苦,温,归心、胃经。开窍豁痰,醒神益智,化湿和胃。苦而性温,芳香而升散。功可上开心窍,中化脾湿。善于治疗痰浊蒙蔽心窍之神昏、失眠、健忘癫痫等症。《重庆堂随笔》云:“清解药用之,赖以祛瘀秽之浊而卫宫城;滋养药用之,借以宣心思之结而通神明。”
上五味,共为臣药,方中党参与黄芪相配,二药皆入脾经,且长于养血生津,补益气血,既可治疗内热过盛耗伤营阴,又可用于治疗气虚血滞引起的卒中后肢体麻木,半身不遂,痹痛等症。龙骨,远志,石菖蒲,三药相配,可治疗卒中后抑郁引起的心神不安,失眠等症,且重镇安神,又长于治疗痰蒙神窍,豁痰以开郁。
蒲黄:甘,平。归肝、心包经,止血,化瘀,蒲黄甘缓不峻,性平无寒热之偏,长于收敛止血,又能活血行瘀。《本草汇言》言其“血之滞者可行,血之行者可止”。
丹皮:苦、辛,微寒。归心、肝、肾经,清热凉血,活血化瘀,辛行苦泄,有活血祛瘀之功。
桑叶:味甘苦,性寒。入肺、肝经。疏散风热,平抑肝阳。入肝经,能清肝热,平肝阳,明目,凉血,用治肝阳上亢,头痛眩晕。
上三味,共为佐药,三药相配,长于活血行血,用于治疗卒中后引起的各种血滞不通,且三药擅于清热,可治疗心脾内热,因虚致实之热。
诸药合用,全方共奏醒神解郁,滋阴清热之功。本方在注重滋阴清热的同时,也兼顾患者的气血运行情况,补气又不忘行气,补血又不忘活血,且注重患者继发郁证,又加以醒神开窍之药物,共同协调患者症状,可谓攻补兼施,扶正又兼以散邪。
本发明第二方面提供一种中药制剂,所述中药制剂包含有效量的如上所述的中药组合物。
优选地,所述中药制剂为中药汤剂。
本发明第三方面提供一种中药汤剂的制备方法,将上述的中药组合物压片后,加水进行煎煮,得到所述中药汤剂。
优选地,包括以下技术特征中的至少一项:
C1)所述压片前,还包括将所述治疗抑郁症的组合物浸泡30-60min;
C2)所述加水至淹没所述治疗抑郁症的组合物2-3cm;
C3)所述煎煮包括第一次煎煮和第二次煎煮,所述煎煮的时间为半个小时,温度为95-100℃;
C4)所述煎煮时,龙骨先煎;
C5)所述煎煮时,蒲黄包煎;
C6)所述煎煮时,桑叶后下。
优选地,所述第二次煎煮的用水量为所述第一次煎煮用水量的2/3-1。
本发明第四方面提供一种中药汤药,由上述的制备方法制得。
本发明第五方面提供上述的中药组合物,上述的中药制剂,上述的中药汤剂在治疗抑郁症的药物中的用途。
优选地,所述抑郁症为卒中后抑郁症。
本发明具有以下有益效果:
本发明适用于卒中后抑郁患者,针对郁损心脾内热之病机,调整免疫因子水平,显著改善卒中后抑郁患者日常生活能力与抑郁程度等典型临床症状。故本发明中的中药组合物适用于卒中后应激状态下的易感人群,如伴运动障碍、言语障碍及日常生活能力障碍的人群,并对卒中后抑郁患者的免疫功能有明显调整作用。
附图说明
图1为本发明实施例8正常组、假手术组、卒中后抑郁组、中药组、舍曲林组中CD4+,CD8+结果图。
具体实施方式
为了使本发明的发明目的、技术方案和有益技术效果更加清晰,以下结合实施例对本发明进行进一步详细说明,熟悉此技术的人士可由本说明书所揭露的内容容易地了解本申请发明的其他优点及功效。
实施例1
按重量份计,取用于治疗抑郁症的中药组合物中各药效成分,分别为:石菖蒲15g,黄芪25g,党参25g,远志24g,蒲黄15g,丹皮9g,桑叶9g,麦冬30g,龙骨15g。将其加水进行煎煮,得到所述治疗抑郁症的中药汤剂1#。
实施例2
按重量份计,取用于治疗抑郁症的中药组合物中各药效成分,分别为:石菖蒲15g,黄芪10g,党参10g,远志10g,蒲黄5g,丹皮5g,桑叶5g,麦冬15g,龙骨5g。将其加水进行煎煮,得到所述治疗抑郁症的中药汤剂2#。
实施例3
按重量份计,取用于治疗抑郁症的中药组合物中各药效成分,分别为:石菖蒲30g,黄芪40g,党参35g,远志30g,蒲黄25g,丹皮20g,桑叶20g,麦冬40g,龙骨30g。将其加水进行煎煮,得到所述治疗抑郁症的中药汤剂3#。
实施例4
按重量份计,取用于治疗抑郁症的中药组合物中各药效成分,分别为:石菖蒲20g,黄芪15g,党参15g,远志15g,蒲黄10g,丹皮5g,桑叶5g,麦冬20g,龙骨10g。将其加水进行煎煮,得到所述治疗抑郁症的中药汤剂4#。
实施例5
按重量份计,取用于治疗抑郁症的中药组合物中各药效成分,分别为:石菖蒲20g,黄芪35g,党参30g,远志25g,蒲黄20g,丹皮15g,桑叶15g,麦冬35g,龙骨25g。将其加水进行煎煮,得到所述治疗抑郁症的中药汤剂5#。
实施例6
选择2020年1月~2020年9月就诊于我院卒中后抑郁患者90例作为研究对象,按随机数表法分为对照组和治疗组1、治疗组2、治疗组3、治疗组4和治疗组5两组,每组各15例。
诊断标准:
西医诊断标准
①缺血性脑卒中诊断符合中华医学会中国第4届脑血管病学术会议制定的脑血管病诊断标准,并经头颅CT或MRI确诊。②抑郁诊断符合美国精神障碍诊断与统计手册第五版(DSM-V)、中国精神疾病分类与诊断标准第3版(CCMD-3)抑郁症的诊断标准及卒中后抑郁临床实践的中国专家共识,且明确发生于卒中后。
中医诊断标准
符合国家中医药管理局《中风病诊断与疗效评定标准》及《中医病证诊断疗效标准·郁病》中郁病的诊断标准。中医辨证分型:根据《中华人民共和国国家标准中医临床诊疗术语证候部分》、田德禄主编的《中医内科学·郁证》将抑郁症辨证为心脾内热证,主症:忧愁善感、兴趣索然、食欲不振、神疲乏力、五心烦热、寐欠佳。次症:心悸,咽干,口燥。舌脉:舌红苔黄腻质干脉弦滑。在中风病诊断成立的前提下,兼见以上2项主症或2项次症,并参考舌脉即可确诊。
纳入标准:
符合西医中度抑郁诊断标准及中医辨证心脾内热证标准;
抑郁程度采用汉密顿抑郁量表(HAMD-17)量化评分,评分>17分为抑郁入组;年龄在18~75岁之间;神志清楚可配合各项测试和检查,MMSE:文盲>17分,小学>20分,初中及以上>24分;中医辨证为心脾内热者;入组前2周未服用其它抗精神病药及抗抑郁药物;签署知情同意书,志愿受试。
排除标准:
同时患有其它精神类疾病,如躁狂症、精神分裂症等;卒中前已经确认为或询问病史考虑明显存在抑郁状态;有严重的自杀倾向者(入组时HAMD-17评分自杀指数>2分);聋、哑、失语及意识障碍、存在明显智力障碍或其他原因而无法配合检查;脑出血、蛛网膜下腔出血及癫痫患者;已知酗酒或药物依赖者;妊娠期、哺乳期妇女;最近一月内参加过其它临床药物观察者;既往对研究药物过敏者。
方法:
对照组给予患者常规对症治疗;治疗组1给予患者口服本发明的实施例1的中药汤剂1#,口服7剂/周,连续治疗8周。
治疗组2给予患者口服本发明的实施例2的中药汤剂1#,口服7剂/周,连续治疗8周。
治疗组3给予患者口服本发明的实施例3的中药汤剂1#,口服7剂/周,连续治疗8周。
治疗组4给予患者口服本发明的实施例4的中药汤剂1#,口服7剂/周,连续治疗8周。
治疗组5给予患者口服本发明的实施例5的中药汤剂1#,口服7剂/周,连续治疗8周。
观察指标:
日常生活能力评分:采用Barthel指数法评分,包括8项(进食、转移、个人卫生、洗澡、穿衣、用厕、大、小便控制)评估自我照顾能力,2项(活动和上下楼梯)评定活动能力。评分0~20分为极严重功能缺陷,生活完全需要依赖;25~45分为严重功能缺陷,生活需要很大帮助;50~70分为中度功能缺陷,生活需要帮助;75~95分为轻度功能缺陷,生活基本自理。满分100分为自理。于治疗前和治疗后2、4、8周进行评价。
HAMD抑郁量表评分:Hamilton Depression Scale是英国学者M.Hamiltion 1960年发展出来的抑郁证量表,本研究采用17项版本,每一个项目采用0~4分的5级评分法,本研究选取HAMD评分总分在17分以上的中重度患者于治疗前和治疗后(2周、4周、8周)进行评价。
分析对照组和治疗组1的结果如下:
1、两组BI评分比较:2组治疗前BI评分比较差异无统计学意义(P>0.05);治疗后2周BI评分比较差异无统计学意义(P>0.05);但治疗4周后和治疗8周后,治疗组BI评分均高于对照组,差异有统计学意义(均P<0.05);2组治疗2、4、8周与治疗前BI评分比较,差异均有统计学意义(均P<0.05),如下表所示:
1、与本组治疗前相比,P<0.05;
2、与本组治疗后2周相比,P<0.05;
3、与本组治疗后4周相比,P<0.05;
4、与对照组同期相比,P<0.05。
注:以上表格中数字右上角的标注分别代表下面关于P值的分析。
2、两组HAMD评分比较:2组治疗前HAMD评分比较差异有统计学意义(P<0.05);治疗后2、6、10周分别与治疗前HAMD评分相比,差异均有统计学意义(均P<0.05),治疗组治疗后2、4、8周HAMD评分均低于对照组,差异有统计学意义(均P<0.05),如下表所示:
1、与本组治疗前相比,P<0.05;
2、与本组治疗后2周相比,P<0.05;
3、与本组治疗后4周相比,P<0.05;
4、与对照组同期相比,P<0.05。
注:以上表格中数字右上角的标注分别代表下面关于P值的分析。
实施例7
病例1
李某某,女性,45岁,上海市第七人民医院门诊号:P102**54
初诊:
主诉:睡眠差、心情差1年,加重20天。
病史:1年前,患者曾因“头晕,右侧肢体无力”入住我院,诊断为“脑梗死”,对症治疗后遗留有右侧肢体无力,近1年来反复出现失眠,整夜无法入睡,精神状态差,心烦易怒;兴趣减退;伴有头晕、全身乏力、食欲减退等,就诊于区精神卫生中心,诊断为“抑郁症”,给予口服“阿戈美拉汀25mg/日、奥氮平5mg/晚”,服药后睡眠好转,但仍有心情差,半年后自行停药。此后上述症状逐渐加重,就诊于我科门诊。近日来,时有紧张焦虑,面色少华,心悸,胸闷,胃纳少、四肢倦怠、夜寐差、多愁善感、兴趣索然。
舌脉:舌红苔黄腻质干脉弦滑
检查:HAMD(汉密尔顿抑郁量表):20,头颅磁共振血管成像(MRA)提示“双侧大脑后动脉多发局限性狭窄”,甲状腺功能正常。
辨证:郁损心脾内热证
诊断:卒中后抑郁
治则:醒神解郁,滋阴清热
方药:中药汤剂1#,14剂
二诊:服药后患者右侧肢体无力症状明显改善,肌力IV级,情绪较前明显好转,心悸症状缓解,胸闷症状未缓解,胃纳较前改善,睡眠质量较前改善,虽难以入睡,但睡后不易醒,HAMD(汉密尔顿抑郁量表):13,舌红苔黄腻质干脉弦滑。仍守上法,予以上述方药14剂,。
随访:继续坚持服药1月余,患者右侧肢体肌力V级,情绪稳定,无明显心悸胸闷,胃纳可,夜寐安,HAMD(汉密尔顿抑郁量表):10,舌淡红苔薄白脉浮。
病例2
张某,男性,55岁,上海市第七人民医院门诊号:443**28
初诊:
主诉:情绪低落,全身乏力、心烦易怒持续50天。
病史:1年前,李某患脑梗在当地医院内科住院治疗,出院后行动无异常,遗留有右上肢肌力稍差。出院后,患者经常出现情绪低落,心慌,心悸伴有全身乏力,整日担心生命垂危。近50天来,症状持续加重,心烦易怒,紧张焦虑,神疲乏力,食欲下降,体重减轻,夜寐差。
舌脉:舌红苔黄腻脉弦滑
检查:HAMD(汉密尔顿抑郁量表):22,头颅磁共振血管成像(MRA)提示“双侧大脑后动脉多发局限性狭窄”,甲状腺功能正常。
辨证:郁损心脾内热证
诊断:卒中后抑郁
治则:醒神解郁,滋阴清热
方药:中药汤剂1#,共14剂
二诊:服药后患者右上肢肌力较前明显改善,紧张缓解,心慌心悸改善,胃纳较佳,易入睡但易醒,HAMD:15,舌尖红苔黄,脉弦滑。仍守上法,予以上述方药14剂。
随访:继续坚持服药1月余,患者右上肢肌力评级为Ⅴ级,情绪稳定,无明显心慌心悸,胃纳可,夜寐安,HAMD:7,舌淡红苔薄白脉浮。
病例3
杨某,女性,53岁,上海市第七人民医院门诊号:435**24
初诊:
主诉:睡眠差2年,加重20天。
病史:2年前,杨某因“头痛伴左侧肢体无力”入住我院,诊断为“脑出血”,对症治疗后遗留有左侧肢体无力,出院后,患者经常出现出现失眠,记忆减退,整夜无法入睡,精神焦虑;情绪低落。近20天来,症状持续加重,心烦易怒,紧张焦虑,神疲乏力,食欲下降,体重减轻,夜寐差。
舌脉:舌红苔黄腻脉弦滑
检查:HAMD(汉密尔顿抑郁量表):24,头颅磁共振血管成像(MRA)提示“双侧大脑后动脉多发局限性狭窄”,甲状腺功能正常。
辨证:郁损心脾内热证
诊断:卒中后抑郁
治则:醒神解郁,滋阴清热
方药:中药汤剂2#,按治疗组1用法服药,共14剂
二诊:服药后患者左侧肢体肌力较前稍有改善,不易入睡,紧张焦虑缓解,记忆力较前明显改善,胃纳较佳,HAMD:19,舌尖红苔黄,脉弦滑。仍守上法,予以上述方药14剂。
随访:继续坚持服药1月余,患者左侧肢体肌力评级为IⅤ级,睡后易醒,情绪稳定,计算力定向力尚可,胃纳可,HAMD:14,舌淡红苔薄白脉浮。
病例4
林某,男性,55岁,上海市第七人民医院门诊号:340**38
初诊:
主诉:情绪低落50天,加重10天。
病史:50天前,林某因“头晕伴右侧肢体无力1天”入住我院,诊断为“脑梗死”,对症治疗后遗留有右侧肢体无力,出院后,患者经常出现情绪低落,哭泣,烦躁,心慌,心悸,记忆力较前明显减退,食欲差,悲观,整日消极避世。近10天来,症状持续加重,心烦易怒,紧张焦虑,神疲乏力,食欲下降,体重减轻,夜寐差。
舌脉:舌红苔黄腻脉弦滑
检查:HAMD(汉密尔顿抑郁量表):22,头颅磁共振血管成像(MRA)提示“右侧大脑中动脉和左侧大脑后动脉局限狭窄”,甲状腺功能正常。
辨证:郁损心脾内热证
诊断:卒中后抑郁
治则:醒神解郁,滋阴清热
方药:中药汤剂3#,按治疗组1用法服药,共14剂
二诊:服药后患者右侧肢体肌力未见明显改善,记忆力稍有改善,紧张缓解,心慌心悸时有,胃纳较佳,睡眠较前无明显改善,HAMD:17,舌尖红苔黄,脉弦滑。仍守上法,予以上述方药14剂。
随访:继续坚持服药1月余,患者右侧肢体肌力评级为IⅤ级,情绪稳定,记忆力较前明显增强,心慌心悸改善,胃纳可,夜寐稍安,HAMD:18,舌淡红苔薄白脉浮。
病例5
高某,男性,47岁,上海市第七人民医院门诊号:678**23
主诉:失眠伴情绪低落3月余。
病史:半年前,高某因“突发言语不利伴右侧口角歪斜2日”入住我院,诊断为“脑梗死”,出院后行动无异常,遗留有右上肢肌力稍差。出院后,患者经常出现情绪低落,口舌干燥,注意力差,睡眠差,入睡困难,易惊醒,早醒,为人淡漠。近3月以来,症状持续加重,心烦易怒,紧张焦虑,神疲乏力,食欲下降,体重减轻,夜寐差。
舌脉:舌红苔黄腻脉弦滑
检查:HAMD(汉密尔顿抑郁量表):24,头颅磁共振血管成像(MRA)提示“双侧大脑后动脉多发局限性狭窄”,甲状腺功能正常。
辨证:郁损心脾内热证
诊断:卒中后抑郁
治则:醒神解郁,滋阴清热
方药:中药汤剂4#,按治疗组1用法服药,共14剂
二诊:服药后患者右上肢肌力稍有改善,时有焦虑紧张,时有口干,胃纳较佳,易入睡但易醒,HAMD:19,舌尖红苔黄,脉弦滑。仍守上法,予以上述方药14剂。
随访:继续坚持服药1月余,患者右上肢肌力评级为IⅤ级,紧张焦虑较前明显缓解,口干时有,胃纳可,夜寐安,HAMD:14,舌淡红苔薄白脉浮。
病例6
王某,女性,60岁,上海市第七人民医院门诊号:532**45
主诉:失眠伴心烦易怒50天。
病史:2年前,王某患脑梗在当地医院神经内科住院治疗,诊断为“脑出血”,采用对症治疗后出院,出院后行动无异常,遗留有左上肢肌力稍差。出院后,患者经常出现失眠,头晕,情绪不稳定,心慌,心悸,乏力,整日郁郁寡欢,做事无兴趣。近50天来,症状持续加重,心烦易怒,紧张焦虑,神疲乏力,食欲下降,体重减轻,夜寐差。
舌脉:舌红苔黄腻脉弦滑
检查:HAMD(汉密尔顿抑郁量表):24,头颅磁共振血管成像(MRA)提示“左侧大脑中动脉和右侧大脑后动脉局限狭窄”,甲状腺功能正常。
辨证:郁损心脾内热证
诊断:卒中后抑郁
治则:醒神解郁,滋阴清热
方药:中药汤剂5#,按治疗组1用法服药,共14剂
二诊:服药后患者左上肢肌力较前明显改善,心慌心悸改善,时有头晕,胃纳较佳,易入睡但易醒,HAMD:20,舌尖红苔黄,脉弦滑。仍守上法,予以上述方药14剂
随访:继续坚持服药1月余,患者左上肢肌力评级为IⅤ级,无明显心慌心悸,头晕改善,胃纳可,入睡可,但时易醒,HAMD:18,舌淡红苔薄白脉浮。
实施例8
以下通过动物试验来观察和评价本发明的中药组合物在治疗卒中后抑郁的作用机制。
材料与方法
1.1材料
1.1.1实验动物
成年SPF级维通利华Sprague-Dawley(SD)大鼠,雄性,体质量220-250g。饲养与上海中医药大学实验动物中心,温度23℃±2℃,湿度55%-60%,自由饮水饮食,昼夜周期24h对半。本研究中的动物实验完全按照国家相关法律及动物伦理学要求,经上海中医药大学动物中心动物伦理委员会批准后进行,伦理编号PZSHUTCM210507005。
1.1.2试剂及药品
盐酸舍曲林片(国药准字H10980141),辉瑞制药有限公司。
中药组成为实施例1中药汤剂1#,由上海市第七人民医院中药房提供。
1.2实验方法
1.2.1大脑中动脉缺血再灌注模型制备(middle cerebral artery occlusion,MCAO模型)
腹腔注射3%戊巴比妥钠(30mg/kg)将大鼠麻醉,使其处于仰卧位并固定四肢。在大鼠颈部沿正中线做3-4cm切口,完全分离右侧颈总动脉(Common carotid artery,CCA)、颈外动脉(External carotid artery,ECA)和颈内动脉(Internal carotid artery,ICA)。用微型动脉夹夹闭CCA近心端、ICA近心端,结扎ECA近心端,使三条血管夹闭点以内血流完全阻断。用眼科剪在ECA上剪一小口,将线栓从ECA插入并转向插入到ICA。松开ICA动脉夹,使线栓顺行插入到大脑中动脉,注意避免插入到翼腭动脉。线栓插入1.5h后拔出,结扎ECA小口两端并松开CCA动脉夹,使血流再灌注到大脑中动脉。清理创口并缝合皮肤,将大鼠侧卧位放回笼盒中以避免舌根后坠阻碍呼吸。手术过程中环境温度维持在25℃~30℃,肛温维持在37.0℃±0.5℃直至动物苏醒。大鼠苏醒后按照Zausinger法对其进行神经功能缺损评分,将评分1-4分的大鼠纳入研究。
1.2.2卒中后抑郁模型制备(PSD模型)
按上述方法成功制备MCAO模型的大鼠在术后3天后,再给与为期28天的慢性不可预期温和型刺激(chronic unpredictable mild stress,CUMS)以制备卒中后抑郁模型,包括禁食24h,禁水24h,潮湿垫料24h,暴露异物24h,行为限制2h,空瓶暴露1h,强迫游泳5min,倾笼7h。每天随机给与2种不同刺激以避免对同一刺激产生耐受性。
1.2.2分组及干预
采用EXCEL随机数字发生器将40只大鼠编号,随机分为假手术组,卒中后抑郁组,中药组,舍曲林组,每组8只。假手术组在MCAO术中只分离动脉而不阻断。术后不给与CUMS刺激,以常规方式饲养。其余四组均先建立PSD模型,在第28天测出抑郁表型后不再给与CUMS刺激,以常规方式饲养。在此基础上,从第29天起中药组给中药灌胃,连续14天,每天1次;舍曲林组给与舍曲林灌胃,连续14天,每天1次。假手术组和卒中后抑郁组同步给与生理盐水灌胃。
1.3流式细胞CD4+,CD8+检测
(1)通过密度梯度离心法,分离抗凝外周全血中的外周血单个核细胞(PBMCs);
(2)细胞计数:对各组细胞进行细胞计数,分别在流式细胞管中加入约2×106的细胞样品;
(3)细胞荧光染色:将各细胞样品用染色缓冲液清洗1遍(1300rpm 5min 4℃离心),加入Anti-CD4-FITC抗体与Anti-CD8-PE抗体,放置于4℃中孵育30min。染色终止时加入2ml/管染色缓冲液,1300rpm 4℃离心5min,并弃去上清。
(4)流式细胞仪分析:每管样品用流式细胞仪进行检测,数据用IDEAS Software进行分析。
1.4结果
如图1,实验结果显示,中药组较卒中后抑郁组外周血中CD8+的细胞毒性T(CTL)细胞的细胞比例明显下降,其余各组与卒中后抑郁组比较均为统计学差异。虽然CD4+的辅助性T(Th)比例统计学上未见明显变化,但其变化趋势与CTL细胞比例变化一致,提示各组药物干预对两类细胞的调控方向一致。
上述实施例仅例示性说明本发明的原理及其功效,而非用于限制本发明。任何熟悉此技术的人士皆可在不违背本发明的精神及范畴下,对上述实施例进行修饰或改变。因此,举凡所属技术领域中具有通常知识者在未脱离本发明所揭示的精神与技术思想下所完成的一切等效修饰或改变,仍应由本发明的权利要求所涵盖。
Claims (10)
3.一种中药制剂,其特征在于,所述中药制剂包含有效量的如权利要求1或2所述的中药组合物。
4.根据权利要求4所述一种中药制剂,其特征在于,所述中药制剂为中药汤剂。
5.一种中药汤剂的制备方法,其特征在于,将权利要求1或2所述的中药组合物压片后,加水进行煎煮,得到所述中药汤剂。
6.如权利要求5所述的中药汤剂的制备方法,其特征在于,包括以下技术特征中的至少一项:
C1)所述压片前,还包括将所述治疗抑郁症的组合物浸泡30-60min;
C2)所述加水至淹没所述治疗抑郁症的组合物2-3cm;
C3)所述煎煮包括第一次煎煮和第二次煎煮;
C4)所述煎煮时,龙骨先煎;
C5)所述煎煮时,蒲黄包煎;
C6)所述煎煮时,桑叶后下。
7.如权利要求6所述的中药汤剂的制备方法,其特征在于,所述第二次煎煮的用水量为所述第一次煎煮用水量的2/3-1。
8.一种中药汤药,由权利要求5-7任一项所述的制备方法制得。
9.如权利要求1或2所述的中药组合物,或如权利要求3或4所述的中药制剂,或权利要求8所述的中药汤剂在治疗抑郁症的药物中的用途。
10.根据权利要求9所述的用途,其特征在于,所述抑郁症为卒中后抑郁症。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310121339.6A CN116370571B (zh) | 2023-02-15 | 一种中药组合物、复方汤药及其制备方法及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310121339.6A CN116370571B (zh) | 2023-02-15 | 一种中药组合物、复方汤药及其制备方法及应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116370571A true CN116370571A (zh) | 2023-07-04 |
CN116370571B CN116370571B (zh) | 2024-06-25 |
Family
ID=
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101318003A (zh) * | 2008-07-11 | 2008-12-10 | 王跃进 | 用于抑郁症中药胶囊 |
CN101850090A (zh) * | 2010-05-25 | 2010-10-06 | 刘宗英 | 一种治疗失眠抑郁的中药制剂 |
CN102416148A (zh) * | 2011-12-08 | 2012-04-18 | 南京海昌中药集团有限公司 | 一种治疗抑郁症的药物和制备方法及其应用 |
CN103142843A (zh) * | 2013-04-07 | 2013-06-12 | 李伟丽 | 一种护理或防治抑郁症的药物组合物 |
CN105412843A (zh) * | 2015-12-30 | 2016-03-23 | 南京中医药大学 | 具有增强记忆,改善抑郁情绪作用的中药组合物及其制备方法与应用 |
CN107158315A (zh) * | 2017-05-03 | 2017-09-15 | 周婕 | 一种治疗失眠抑郁的中药制剂 |
CN113368206A (zh) * | 2021-07-30 | 2021-09-10 | 大连医科大学附属第一医院 | 一种治疗卒中后抑郁的中药组合物 |
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101318003A (zh) * | 2008-07-11 | 2008-12-10 | 王跃进 | 用于抑郁症中药胶囊 |
CN101850090A (zh) * | 2010-05-25 | 2010-10-06 | 刘宗英 | 一种治疗失眠抑郁的中药制剂 |
CN102416148A (zh) * | 2011-12-08 | 2012-04-18 | 南京海昌中药集团有限公司 | 一种治疗抑郁症的药物和制备方法及其应用 |
CN103142843A (zh) * | 2013-04-07 | 2013-06-12 | 李伟丽 | 一种护理或防治抑郁症的药物组合物 |
CN105412843A (zh) * | 2015-12-30 | 2016-03-23 | 南京中医药大学 | 具有增强记忆,改善抑郁情绪作用的中药组合物及其制备方法与应用 |
CN107158315A (zh) * | 2017-05-03 | 2017-09-15 | 周婕 | 一种治疗失眠抑郁的中药制剂 |
CN113368206A (zh) * | 2021-07-30 | 2021-09-10 | 大连医科大学附属第一医院 | 一种治疗卒中后抑郁的中药组合物 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112190638A (zh) | 一种治疗脑梗死恢复期卒中后失眠的中药组合物及其应用 | |
CN101810787B (zh) | 一种治疗心烦的中药组合物及其制备方法 | |
CN116370571B (zh) | 一种中药组合物、复方汤药及其制备方法及应用 | |
CN101628104B (zh) | 一种用于治疗抑郁症的中药组合物 | |
CN115252753B (zh) | 治疗失眠的中药组合物及其应用 | |
CN104189819B (zh) | 一种用于调理情绪健康的中药制剂 | |
CN101049345B (zh) | 一种治疗口腔和咽喉疾病的制剂及其制备方法 | |
CN106237268B (zh) | 一种治疗精神分裂症的药物组合物及其应用 | |
CN116370571A (zh) | 一种中药组合物、复方汤药及其制备方法及应用 | |
CN102205044B (zh) | 一种治疗咳喘的药物 | |
CN101664518B (zh) | 滋润浴液组合物、其制备方法及其在制备治疗阴血虚疲劳综合症肥胖症药品保健品中的应用 | |
CN108143929B (zh) | 一种治疗血管性痴呆的药物 | |
CN102813849B (zh) | 一种治疗喘促型急性肾小球肾炎的中药制备方法 | |
CN102872292B (zh) | 一种治疗脾肾两虚型缺血性卒中后抑郁症的中药 | |
CN107349359B (zh) | 一种能够解酒的中药组合物 | |
CN107184701B (zh) | 一种治疗精神分裂症的中药组合物、制备方法及其应用 | |
CN104524252A (zh) | 一种治疗癫狂症的中药制剂 | |
CN116920052B (zh) | 一种治疗原发性干燥综合征伴抑郁症的中药组合物及其制备方法和应用 | |
CN116139236B (zh) | 一种治疗肝郁型失眠症的中药组合物及其应用 | |
CN100998744A (zh) | 一种治疗小儿多动症的中成药 | |
CN109663012A (zh) | 疏风清热,解毒利咽中药组合物及其制备方法与应用 | |
CN115068570B (zh) | 一种解酒护肝的黎药组合物及其制备方法和应用 | |
CN104383449B (zh) | 一种治疗郁病的药物组合物 | |
CN116196375B (zh) | 一种用于预防和/或治疗失眠的复方精油 | |
CN118001323B (zh) | 一种用于防治焦虑症的中药组合物及其制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant |